Logo do repositório
 
Publicação

A state of the art review on the novel mediator asprosin in the metabolic syndrome

2020Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorLuís, Carla
dc.contributor.authorFernandes, Rúben
dc.contributor.authorSoares, Raquel
dc.contributor.authorVon-Hafe, Pedro
dc.date.accessioned2021-10-19T13:42:48Z
dc.date.available2021-10-19T13:42:48Z
dc.date.issued2020
dc.description.abstractMetabolic syndrome is a complex and heterogeneous pathology characterized by a cluster of biochemical, clinical, and metabolic factors that came together in raising the risk of cardiovascular diseases, type 2 diabetes mellitus, and all-cause mortality. Some of these features are well defined in this syndrome like: obesity, inflammation, hypertension, insulin resistance, atherosclerotic dyslipidemias, endothelial dysfunction, and inflammation. This circuit is intermediated by a complex network of hormones, cytokines, transcription factors, and adipokines, among others. Some like leptin, adiponectin, Plasminogen activator inhibitor-1, interleukin-6, Tumor necrosis factor, and their influence on the metabolic syndrome are well described in the literature and new players are described continuously. One novel player was described in 2016 by Romere et al as a fasting-induced glycogenic protein hormone named asprosin.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationLuís, C., Fernandes, R., Soares, R., & von Hafe, P. (2020). A state of the art review on the novel mediator asprosin in the metabolic syndrome. Porto Biomedical Journal, 5(6), e108. https://doi.org/10.1097/j.pbj.0000000000000108pt_PT
dc.identifier.doi10.1097/j.pbj.0000000000000108pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.22/18736
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWolters Kluwerpt_PT
dc.relation.publisherversionhttps://journals.lww.com/pbj/Fulltext/2020/12000/A_state_of_the_art_review_on_the_novel_mediator.22.aspxpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectSCFAspt_PT
dc.subjectTMAOpt_PT
dc.subjectAtherosclerosispt_PT
dc.subjectCardiovascular diseasespt_PT
dc.subjectGut microbiotapt_PT
dc.subjectHypertensionpt_PT
dc.titleA state of the art review on the novel mediator asprosin in the metabolic syndromept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage7pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titlePorto Biomedical Journalpt_PT
oaire.citation.volume5pt_PT
person.familyNameFernandes
person.givenNameRúben
person.identifier635792
person.identifier.ciencia-id0D1F-4090-E82A
person.identifier.orcid0000-0001-8933-3984
person.identifier.scopus-author-id57640135700
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication9e6c397c-62d8-4a40-8ec7-ad05ae0ebcc4
relation.isAuthorOfPublication.latestForDiscovery9e6c397c-62d8-4a40-8ec7-ad05ae0ebcc4

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
ART_Rúben Fernandes 1.pdf
Tamanho:
2.47 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

ESS - CQB - Artigos